This content is from: Research
Economics & Strategy - Socially Responsible Investing: Second
Newcomer Julie Hudson — who, according to one supporter, “has a broad and deep experience of the equity markets, both in terms of sectors and geographies” — guides the previously unranked UBS trio to second place.
SECOND TEAM
Julie Hudson & team UBS
Newcomer Julie Hudson who, according to one supporter, has a broad and deep experience of the equity markets, both in terms of sectors and geographies guides the previously unranked UBS trio to second place. In November the analysts teamed up with Gbola Amusa, the firms head of European pharmaceuticals research, to publish a report recommending GlaxoSmithKline, at 1,223p, making the case that the Brentford, Englandbased pharmaceuticals manufacturer has a history of distributing drugs free of charge in emerging markets where there are unmet medical needs and that the company is well positioned to expand its operations within those markets, which represent a key growth opportunity over the long term. By the end of the year, the stock had risen to 1,240p.